ABVC BioPharma, Inc. filings document the regulatory record of a Nevada clinical-stage biopharmaceutical company focused on ophthalmology, CNS, and oncology/hematology programs. The company’s disclosures include Form 8-K reports for financial results and material events, proxy materials for annual shareholder meetings, board elections, and shareholder voting results.
ABVC’s SEC filings also cover governance and capital-structure matters, including unregistered common stock sales under Regulation S, voting-rights proxy arrangements connected to those sales, director and officer compensation arrangements, changes in the company’s independent registered public accounting firm, and formal reporting around shareholder approvals and corporate controls.
ABVC BioPharma, Inc. reported that its previously issued financial statements for the quarter ended September 30, 2025 should no longer be relied upon because of errors in revenue recognition and fair value measurement. The company reversed an aggregate $795,950 of licensing revenue from OncoX and ForSeeCon after determining much of the cash effectively came from related party BioFirst or did not meet contractual payment conditions, and reclassified those amounts to balances with BioFirst and OncoX.
ABVC also remeasured land acquired from director Shuling Jiang, concluding that the fair value of the equity and warrants issued provides a clearer measure than the prior appraisal-based value. This increased the recorded land cost by $798,486 to $4,656,461. The company identified a material weakness in internal control over financial reporting and plans to amend the affected Form 10-Q. Separately, ABVC’s 2025 Form 10-K shows total assets rising 179% to $21.06 million, driven mainly by strategic land and development-oriented assets in Asia.
ABVC BioPharma, Inc. is asking shareholders to approve three items at its 2026 virtual annual meeting on March 9, 2026. Shareholders will vote on re-electing 11 directors, ratifying Simon & Edward, LLP as auditor for 2026, and increasing shares under the 2016 Equity Incentive Plan.
The equity plan amendment would raise the plan reserve to an amount equal to 15% of the company’s 25,423,654 shares of common stock outstanding as of January 26, 2026, which is estimated at 3,813,548 shares, with a continuing 5% annual “evergreen” increase beginning in 2027.
ABVC BioPharma reports additional unregistered equity sales following a prior offshore offering. Between April 11 and May 27, 2025, the company sold 1,987,557 common shares to 43 Non-U.S. Persons under Regulation S, raising aggregate gross proceeds of about $1,289,750.
Between May 26, 2025, and January 6, 2026, ABVC accepted further subscriptions totaling $2,275,468 on the same terms, issuing 1,500,250 additional common shares at prices between $1.00 and $1.95 per share. These new shares equal about 5.92% of the company’s outstanding common stock as of this filing. Investors entered stock purchase agreements and Voting Rights Proxy Agreements transferring their voting rights to chairman Eugene Jiang. The securities were sold privately to accredited, Non-U.S. investors, are unregistered, and are subject to resale restrictions under U.S. securities laws.
ABVC BioPharma filed Prospectus Supplement No. 4 to its July 12, 2024 prospectus, registering 1,000,000 shares of common stock underlying a common stock purchase warrant. The supplement also attaches the company’s Q3 2025 Form 10‑Q. Shares outstanding were 24,301,089 as of October 30, 2025; this is a baseline figure, not the amount being offered.
For the nine months ended September 30, 2025, ABVC reported revenue of $795,950 and a net loss of $4,564,546. The company disclosed a working capital deficit of $2,434,951 and noted substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were $192,068 with restricted cash of $661,843. Total assets rose to $21.18 million, reflecting land acquisitions and other noncurrent items.
ABVC BioPharma filed Prospectus Supplement No. 5 updating its April 5, 2024 prospectus covering 11,714,683 shares of common stock. The supplement appends the company’s Form 10-Q for the quarter ended September 30, 2025.
For Q3 2025, revenue was $795,950 and loss from operations was $1,168,410, leading to a net loss attributable to ABVC of $1,246,513. For the nine months, net loss attributable to ABVC was $4,345,610. Cash and cash equivalents were $192,068 with restricted cash of $661,843 as of September 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern, citing a working capital deficit of $2,434,951 and net cash outflows from operating activities of $1,567,264 for the nine months. Shares outstanding were 24,301,089 as of October 30, 2025; this is a baseline figure, not the amount being offered.
ABVC BioPharma filed Prospectus Supplement No. 5 covering 225,500 shares of common stock and updating its May 22, 2024 prospectus with the company’s Form 10‑Q for the quarter ended September 30, 2025.
For Q3 2025, revenue was $795,950 and net loss attributed to ABVC and subsidiaries was $1,246,513. For the nine months ended September 30, 2025, net loss was $4,564,546. Cash and cash equivalents were $192,068 and restricted cash was $661,843. The filing notes a working capital deficit of $2,434,951 and states there is substantial doubt about the company’s ability to continue as a going concern.
Shares outstanding were 24,301,089 as of October 30, 2025. The company also disclosed restatements affecting 2023 and certain 2024 interim figures, primarily related to stock‑based compensation, convertible note accounting, and noncontrolling interests.
ABVC BioPharma furnished an 8-K to announce its financial results for the third quarter ended September 30, 2025. The company reported these results via a press release attached as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes Exhibit 104, the cover page interactive data file formatted in Inline XBRL. The notice states it is not an offer to sell or solicit purchases of securities.
ABVC BioPharma filed its Q3 2025 Form 10‑Q, reporting revenues of $795,950 for the quarter and $795,950 for the nine months. The company posted a net loss of $1,287,523 for Q3 and $4,564,546 for the nine months, with basic and diluted net loss per share of $0.05 and $0.23, respectively.
Total assets were $21,176,299 as of September 30, 2025, up from $7,539,907 at December 31, 2024, largely reflecting property and equipment, net, of $12,055,642, including land acquisitions in Taiwan. Cash and cash equivalents were $192,068, with restricted cash of $661,843. The company reported a working capital deficit of $2,434,951 and stated that these conditions give rise to substantial doubt about its ability to continue as a going concern.
Operating cash outflow was $1,567,264 for the nine months, offset by $3,488,478 provided by financing activities. The company recognized collaboration revenues from related‑party licensing, including $595,950 from an OncoX agreement and $200,000 from a FEYE amendment during the nine months. ABVC restated prior periods to correct share‑based payment accounting, interest recognition on a convertible note, and non‑controlling interest presentation. Shares outstanding were 24,301,089 as of October 30, 2025.
ABVC BioPharma (ABVC) approved a performance incentive plan for directors, officers, and select employees. The plan will only take effect after the company achieves a $1B market cap for 30 consecutive trading days on or before December 31, 2027, of which there is no guarantee.
If implemented, awards will equal 1% of the company’s common stock outstanding on the implementation date, sourced from the Amended and Restated 2016 Equity Incentive Plan. The plan is capped at $10 million in total awards, with a $1 million cap per recipient. Grants will be tied to defined milestones and require allocation by the Compensation Committee, endorsement by a majority of independent directors, and final approval by the full Board. The structure is intended to align leadership incentives with shareholder value creation.
ABVC BioPharma, Inc. filed an amended current report to update information about its former independent auditor. The company previously disclosed that WWC, P.C., its independent registered public accounting firm, agreed not to renew its engagement as of October 10, 2024.
In this amendment, ABVC explains that it had provided WWC with the earlier report and asked for a letter to the SEC stating whether WWC agreed with the company’s description of the circumstances. ABVC now reports that WWC has refused to provide that letter.